BDMD (Baird Medical Investment Holdings) 5-Year EBITDA Growth Rate : 0.00% (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Baird Medical Investment Holdings 5-Year EBITDA Growth Rate?

Baird Medical Investment Holdings's EBITDA per Share for the six months ended in Jun. 2024 was $0.17.

During the past 12 months, Baird Medical Investment Holdings's average EBITDA Per Share Growth Rate was 350.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Competitive Comparison of Baird Medical Investment Holdings's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Baird Medical Investment Holdings's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baird Medical Investment Holdings's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baird Medical Investment Holdings's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Baird Medical Investment Holdings's 5-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Baird Medical Investment Holdings 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Baird Medical Investment Holdings (NAS:BDMD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Baird Medical Investment Holdings 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Baird Medical Investment Holdings's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Baird Medical Investment Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Baird Medical Investment Holdings Ltd (NAS:BDMD) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.15 Rongtong Street, Room 202, 2nd Floor, Baide Building, Building 11, Yuexiu, Guangzhou, CHN

Website

Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.